Pangea Botanica Email Format
Biotechnology ResearchEngland, United Kingdom11-50 Employees
Pangea Bio is developing novel therapies that directly activate the TrkB receptor, driving neuronal and synaptic plasticity, and neuroprotection. Dysfunction of the BDNF/TrkB pathway is a hallmark of disorders such as schizophrenia, depression, Alzheimer’s disease, Parkinson’s disease, and glaucoma.